| Santmyer, JoAnn |
NCT03642067: Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer |
|
|
| Completed | 2 | 59 | US | Nivolumab, OPDIVO, BMS-936558, anti-PD-1, Relatlimab, BMS-986016, anti-LAG-3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma | 02/24 | 09/24 | | |
NCT06205836: Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer |
|
|
| Recruiting | 2 | 22 | US | Cemiplimab, REGN2810, LIBTAYO, Fianlimab, REGN3767 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Regeneron Pharmaceuticals | Colorectal Cancer | 05/28 | 05/28 | | |
NCT04209686: Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 36 | US | Paclitaxel, Taxol, Olaparib, Lynparza, Pembrolizumab, MK-3475; Keytruda | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Advanced Gastric Adenocarcinoma | 04/28 | 04/28 | | |
NCT03607890: Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor |
|
|
| Recruiting | 2 | 42 | US | Nivolumab, anti-PD-1, OPDIVO, Relatlimab, BMS-986016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI) | Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors | 10/25 | 10/25 | | |
NCT04116073: INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer |
|
|
| Completed | 2 | 25 | US | INCMGA00012 (PD-1 antibody), MGA012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI) | Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic | 08/24 | 12/24 | | |
NCT04753879: Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. |
|
|
| Recruiting | 2 | 38 | US | Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Metastatic Pancreatic Cancer | 12/25 | 12/29 | | |
NCT05604560: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer |
|
|
| Recruiting | 2 | 25 | US | Tislelizumab, BGB-A317, SX-682 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, BeiGene, Syntrix Biosystems, Inc. | Pancreatic Cancer | 09/26 | 09/26 | | |
NCT06001658: Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers |
|
|
| Recruiting | 2 | 27 | US | Gemcitabine, Cisplatin, Pembrolizumab, KEYTRUDA; anti-PD-1 mAb | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Pancreatic Cancer | 06/28 | 06/28 | | |
NCT03767582: Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. |
|
|
| Completed | 1/2 | 46 | US | Stereotactic Body Radiation (SBRT), Nivolumab, OPDIVO, CCR2/CCR5 dual antagonist, BMS-813160, GVAX, PANC 10.05 pcDNA-1/GM-Neo vaccine, PANC 6.03 pcDNA-1/GM-Neo vaccine | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | 09/24 | 09/24 | | |
NCT06445062: Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors |
|
|
| Recruiting | 1/2 | 1130 | US | RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805 | Revolution Medicines, Inc. | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 05/27 | 07/27 | | |
NCT03535727: A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer |
|
|
| Completed | 1/2 | 48 | US | Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Capecitabine, Xeloda, Cisplatin, Platinol, Irinotecan, Camptosar | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular, Neoplasms, Neoplasms Pancreatic, Digestive System Neoplasm, Endocrine Gland Neoplasms, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases | 10/22 | 10/22 | | |
NCT06027086: DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) |
|
|
| Recruiting | 1/2 | 27 | US | Durvalumab, IMFINZI, DRP-104 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dracen Pharmaceuticals, Inc., Fibrolamellar Cancer Foundation | Fibrolamellar Hepatocellular Carcinoma | 08/28 | 08/29 | | |
NCT06411691: KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer |
|
|
| Recruiting | 1 | 50 | US | KRAS Vaccine with Poly-ICLC adjuvant, Hiltonol® (Poly-ICLC), Balstilimab, AGEN2034, Botensilimab, AGEN1181 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Agenus Inc., Private Philanthropic Funds, National Institutes of Health (NIH) | Colorectal Cancer, Pancreatic Cancer | 11/27 | 11/27 | | |
IRB00210915, NCT04117087: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer |
|
|
| Recruiting | 1 | 30 | US | KRAS peptide vaccine, Hiltonol® (Poly-ICLC), Nivolumab, OPDIVO, Ipilimumab, YERVOY® | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH) | Colorectal Cancer, Pancreatic Cancer | 08/25 | 08/25 | | |
NCT05013216: Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer |
|
|
| Recruiting | 1 | 37 | US | Cohort A: Patients at high risk of developing pancreatic cancer., Hiltonol® (Poly-ICLC), Cohort B: Patients must have evidence of a pancreatic cystic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Stand Up To Cancer | High Risk Cancer, Pancreatic Cancer | 05/26 | 05/26 | | |
| Davis, Jenna L |
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors |
|
|
| Recruiting | 1/2 | 198 | Europe, Canada, US, RoW | disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380 | Seagen Inc., RemeGen Co., Ltd. | Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer | 01/30 | 01/30 | | |
NCT06445062: Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors |
|
|
| Recruiting | 1/2 | 1130 | US | RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805 | Revolution Medicines, Inc. | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 05/27 | 07/27 | | |
NCT04294160: A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer |
|
|
| Terminated | 1 | 122 | Europe, Canada, US, RoW | Dabrafenib, DRB436, Tafinlar, LTT462, Trametinib, TMT212, Mekinist, LXH254, TNO155, Spartalizumab, PDR001, Tislelizumab, VDT482, BGBA317 | Novartis Pharmaceuticals | BRAF V600 Colorectal Cancer | 09/24 | 09/24 | | |
| Apostol, Colleen |
RASolute 302, NCT06625320: Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) |
|
|
| Recruiting | 3 | 460 | US | RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin | Revolution Medicines, Inc. | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | 06/26 | 12/27 | | |
NCT06205836: Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer |
|
|
| Recruiting | 2 | 22 | US | Cemiplimab, REGN2810, LIBTAYO, Fianlimab, REGN3767 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Regeneron Pharmaceuticals | Colorectal Cancer | 05/28 | 05/28 | | |
NCT04209686: Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 36 | US | Paclitaxel, Taxol, Olaparib, Lynparza, Pembrolizumab, MK-3475; Keytruda | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Advanced Gastric Adenocarcinoma | 04/28 | 04/28 | | |
NCT05604560: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer |
|
|
| Recruiting | 2 | 25 | US | Tislelizumab, BGB-A317, SX-682 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, BeiGene, Syntrix Biosystems, Inc. | Pancreatic Cancer | 09/26 | 09/26 | | |
NCT06001658: Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers |
|
|
| Recruiting | 2 | 27 | US | Gemcitabine, Cisplatin, Pembrolizumab, KEYTRUDA; anti-PD-1 mAb | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Pancreatic Cancer | 06/28 | 06/28 | | |
NCT03767582: Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. |
|
|
| Completed | 1/2 | 46 | US | Stereotactic Body Radiation (SBRT), Nivolumab, OPDIVO, CCR2/CCR5 dual antagonist, BMS-813160, GVAX, PANC 10.05 pcDNA-1/GM-Neo vaccine, PANC 6.03 pcDNA-1/GM-Neo vaccine | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | 09/24 | 09/24 | | |
NCT06445062: Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors |
|
|
| Recruiting | 1/2 | 1130 | US | RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805 | Revolution Medicines, Inc. | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 05/27 | 07/27 | | |
| Active, not recruiting | 1/2 | 115 | Europe, Canada, US | GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab | Nouscom SRL, Merck Sharp & Dohme LLC | Solid Tumor, Adult | 04/25 | 11/26 | | |
NCT06411691: KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer |
|
|
| Recruiting | 1 | 50 | US | KRAS Vaccine with Poly-ICLC adjuvant, Hiltonol® (Poly-ICLC), Balstilimab, AGEN2034, Botensilimab, AGEN1181 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Agenus Inc., Private Philanthropic Funds, National Institutes of Health (NIH) | Colorectal Cancer, Pancreatic Cancer | 11/27 | 11/27 | | |
IRB00210915, NCT04117087: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer |
|
|
| Recruiting | 1 | 30 | US | KRAS peptide vaccine, Hiltonol® (Poly-ICLC), Nivolumab, OPDIVO, Ipilimumab, YERVOY® | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH) | Colorectal Cancer, Pancreatic Cancer | 08/25 | 08/25 | | |
NCT05013216: Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer |
|
|
| Recruiting | 1 | 37 | US | Cohort A: Patients at high risk of developing pancreatic cancer., Hiltonol® (Poly-ICLC), Cohort B: Patients must have evidence of a pancreatic cystic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Stand Up To Cancer | High Risk Cancer, Pancreatic Cancer | 05/26 | 05/26 | | |
NCT04248569: DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 56 | US | DNAJB1-PRKACA peptide vaccine, Hiltonol® (Poly-ICLC), Nivolumab, OPDIVO, Ipilimumab, YERVOY® | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, Fibrolamellar Cancer Foundation, National Cancer Institute (NCI) | Fibrolamellar Hepatocellular Carcinoma (FLC) | 03/27 | 03/27 | | |
